All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
On March 17, 2021, it was announced that the phase II HERACLES trial (NCT03359980), evaluating MaaT013 in patients with acute graft-versus-host disease (aGvHD), met its primary objective.
This multi-center, single-arm, open-label study evaluated the efficacy and safety of MaaT013, a standardized, high-diversity, pooled-donor microbiome biotherapeutic, in 21 heavily pretreated patients with steroid-refractory Grade III─IV gastrointestinal-predominant aGvHD.
These patients received at least one (and up to three) doses of MaaT013; responses were evaluated 7 days after each administration and on Day 28 after the first dose. The primary endpoint of clinical efficacy was met, with a complete response/very good partial response rate of 33.3% at Day 28. In addition, the overall response rate was 38.1% at Day 28 and the best overall response rate up to Day 28 was 57.1%. The safety profile of MaaT013 was good, with no increase in drug-related infection rates observed in this heavily pretreated and immunocompromised population.
These results were in line with data from the expanded access program, reported here. Based on these positive results, MaaT013 is expected to advance into a pivotal phase III trial.
For further information, watch our recent interview with Florent Malard.
Subscribe to get the best content related to GvHD delivered to your inbox